Publicaciones científicas
Estrogen Receptor and Immune Checkpoint Inhibitors: New Partners in Lung Cancer?
02-oct-2023
| Revista: Clinical Cancer Research
Karmele Valencia 1 2 3 4 5, Luis M Montuenga 1 2 3 5 6, Alfonso Calvo 1 2 3 5 6
Abstract
The influence of sex on immunotherapy response in patients with non-small cell lung cancer (NSCLC) had been studied with no clear conclusions. An article in this issue reports that a key determinant of response is not sex but the existence of a 17β-estradiol/ERα/PDL1 signaling loop in NSCLC. This intriguing result opens new therapeutic options. See related article by Anobile et al., p. 3958.
CITA DEL ARTÍCULO: Clin Cancer Res. 2023 Oct 2;29(19):3832-3834. doi: 10.1158/1078-0432.CCR-23-1736.
Nuestros autores
Investigadora | Investigadora principal
Grupo de investigación en Innovación terapéutica en cáncer de pulmón
Dr.
Alfonso Calvo González